ASAQ, the artesunate-amodiaquine fixed-dose combination, was the first treatment developed by DNDi in partnership with Sanofi, and is produced in Morocco. Developed as a non-patented product, the technology transfer for ASAQ to a second partner in Africa is a vital part of DNDi’s strategy to increase patient access to this treatment, according to the market demand forecast of 100 million treatments.

In 2010, DNDi, with support from a group of experts, assessed various potential partners in Africa in order to ensure that all criteria for a successful technology transfer were met. In  2011, an agreement was signed with a partner in Tanzania – Zenufa.

In 2016, technology transfer to the Tanzanian company Zenufa as a second source of production for the antimalarial ASAQ was finalized. This is in addition to the one produced by Sanofi. Zenufa’s production site in Tanzania is now ‘Good Manufacturing Practice’ certified by the Tanzanian authorities and its prequalification dossier is being finalized for submission to the WHO.

More on ASAQ